PRESS RELEASE published on 11/13/2025 at 08:40, 10 months 4 days ago Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris Inventiva temporarily halts trading of ordinary shares on Euronext Paris for public offering preparation, with expected resumption by end of day. Company focuses on MASH treatment research Euronext Paris Trading Halt Public Offering Inventiva MASH Treatment
BRIEF published on 10/14/2025 at 22:05, 11 months 3 days ago Inventiva Launches New ATM Program to Raise $100 Million Biopharmaceutical SEC Filing Inventiva Lanifibranor ATM Program
PRESS RELEASE published on 10/14/2025 at 22:00, 11 months 3 days ago Inventiva Announces the Implementation of a New ATM Program Inventiva implements new ATM program, files Registration Statement with the SEC for up to $100 million aggregate gross sales proceeds. Proceeds to fund research and development, working capital, and corporate purposes Biopharmaceutical SEC Registration Statement Inventiva ATM Program
BRIEF published on 10/07/2025 at 22:05, 11 months 10 days ago Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor Digital Pathology Inventiva MASH Lanifibranor Liver Meeting 2025
PRESS RELEASE published on 10/07/2025 at 22:00, 11 months 10 days ago Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Inventiva to present multiple abstracts at AASLD The Liver Meeting® 2025 showcasing digital pathology data and therapeutic benefits of lanifibranor in MASH treatment. Visit booth #745 for more Digital Pathology Inventiva MASH Lanifibranor AASLD The Liver Meeting
BRIEF published on 10/01/2025 at 08:35, 11 months 16 days ago Andrew Obenshain Appointed as CEO of Inventiva Leadership Transition Drug Development Inventiva MASH Treatment Andrew Obenshain
PRESS RELEASE published on 10/01/2025 at 08:30, 11 months 16 days ago Inventiva Appoints Andrew Obenshain as Chief Executive Officer Inventiva appoints Andrew Obenshain as Chief Executive Officer, succeeding Frédéric Cren, to lead company's growth and prepare for potential commercialization in the United States Chief Executive Officer Inventiva MASH Frédéric Cren Andrew Obenshain
BRIEF published on 09/24/2025 at 22:05, 11 months 23 days ago Inventiva organizes an event for analysts and investors Event Phase 3 Inventiva MASH Lanifibranor
PRESS RELEASE published on 09/24/2025 at 22:00, 11 months 23 days ago Inventiva to Host Analyst and Investor Event on October 8, 2025 Inventiva to host analyst and investor event on October 8, 2025 featuring updates on lanifibranor and key MASH trends. Renowned experts to share insights on MASH landscape Inventiva Lanifibranor Analyst Event MASH Trends Expert Insights
BRIEF published on 08/25/2025 at 10:02, 1 year ago JP Morgan crosses threshold at Inventiva Voting Rights Actions Threshold Crossing JP Morgan Inventiva
Published on 09/18/2026 at 00:55, 3 hours 1 minute ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 3 hours 31 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 5 hours 41 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/17/2026 at 22:15, 5 hours 41 minutes ago Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
Published on 09/17/2026 at 22:05, 5 hours 51 minutes ago Loop Industries Forms Strategic Alternatives Committee to Maximize Shareholder Value
Published on 09/17/2026 at 19:00, 8 hours 56 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 8 hours 58 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 9 hours 31 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 9 hours 46 minutes ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 10 hours 10 minutes ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 10 hours 16 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 10 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 20 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
